Key result
Inhibition of soluble epoxide hydrolase with TPPU reversed arrhythmogenic cardiomyopathy features and improved left ventricular ejection fraction in animal models.
[Figure: see text]
No takes yet. Share an insight, caveat, or question.
Gao et al. (2025) conducted an editorial in Arrhythmogenic Cardiomyopathy. Soluble epoxide hydrolase (sEH) inhibitors (e.g., TPPU) was evaluated. Inhibition of soluble epoxide hydrolase with TPPU reversed arrhythmogenic cardiomyopathy features and improved left ventricular ejection fraction in animal models.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: